Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Safety Study of Galcanezumab in Japanese Patients with Migraine
jRCT2080223375Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of galcanezumab in migraine and chronic migraine (2 arms), sponsored by Eli Lilly and Company. Started Nov 2016; status: recruiting.
02
Drugs
galcanezumab
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on jRCT2080223375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223375.